Trial
NCT05761301
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alnylam Pharmaceuticals
Collaborators
—
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention
ALN-KHK
Why stopped
Business reasons (not safety related)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-07